WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > UK Chemical and Pharmaceutical Industry Facts and Figures
I'm For Real
Enter your details once to access all our information and resources
Nephron Pharmaceuticals Corporation is a mid-sized company that manufactures generic respiratory medications. NPC sells to many classes of trade, including.
whitePaper | July 11, 2022
The expansion in the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) and complex active pharmaceutical ingredients (APIs) has grown tremendously as demands in healthcare to bring newer therapies to market quicker increase.
whitePaper | May 22, 2021
One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.
whitePaper | April 24, 2023
Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.
whitePaper | June 27, 2022
As the world begins its transition into a postpandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects that COVID-19 has brought.
whitePaper | August 8, 2022
Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.
whitePaper | November 25, 2022
To meet the needs of a growing range of external stakeholders, many life science companies are changing the ways that they disseminate information.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE